lifestyle.digitaladblog.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
KODIAK SCIENCES INC.
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
March 31, 2026
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
March 26, 2026
Final APEX Phase 1b Clinical Results for Kodiak’s KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
February 4, 2026
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 18, 2025
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
December 16, 2025
Kodiak Sciences Announces Proposed Public Offering of Common Stock
December 16, 2025
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
November 16, 2025
Kodiak Sciences to Present at Upcoming Investor Conferences
November 15, 2025
Follow-up data for Kodiak’s KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
November 8, 2025